/
NRIX
$27.19+$0.56 (+2.10%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.8B
104M shares
52-week range
$8.20 – $27.35
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-2.38
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
www.nurixtx.com- Employees
- 357
- IPO / List date
- Jul 24, 2020
- HQ
- BRISBANE, CA
Held by traders on TradeandTell
No one on the platform currently holds NRIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 118,000 | $1.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NRIX yet.
